Scott T. Rottinghaus
Known title: Chief Medical OfficerCIK: 0001942407
Associated companies
Transaction History
| ENTA | ▼ Sell | Tax Withholding | 1,467 | $20K | 8/8/2026 | View on chart |
| ENTA | ▲ Buy | Grant | 1,650 | $0 | 2/12/2026 | View on chart |
| ENTA | ▲ Buy | Grant | 5,225 | $0 | 2/12/2026 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 3,413 | $49K | 2/12/2026 | View on chart |
| ENTA | ▼ Sell | Open Market | 798 | $11K | 12/5/2025 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 2,217 | $15K | 8/8/2025 | View on chart |
| ENTA | ▲ Buy | Grant | 9,750 | $0 | 2/12/2025 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 2,861 | $16K | 2/12/2025 | View on chart |
| ENTA | ▼ Sell | Open Market | 866 | $7K | 12/6/2024 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 1,466 | $19K | 8/8/2024 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 5,375 | $48K | 7/15/2024 | View on chart |
| ENTA | ▼ Sell | Open Market | 5,375 | $92K | 7/15/2024 | View on chart |
| ENTA | ▼ Sell | Open Market | 2,271 | $34K | 7/12/2024 | View on chart |
| ENTA | ▼ Sell | Open Market | 4,299 | $65K | 7/11/2024 | View on chart |
| ENTA | ▲ Buy | Grant | 2,576 | $0 | 2/12/2024 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 755 | $9K | 2/12/2024 | View on chart |
| ENTA | ▼ Sell | Open Market | 534 | $5K | 12/5/2023 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 1,467 | $25K | 8/8/2023 | View on chart |
| ENTA | ▲ Buy | Grant | 7,000 | $0 | 11/23/2022 | View on chart |
| ENTA | ▲ Buy | Grant | 20,000 | $0 | 8/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
HC Wainwright Maintains $20 Target for Enanta
HC Wainwright reiterated its stance on Enanta Pharmaceuticals, keeping a price target of $20. This view aligns with the broader analyst consensus, where the average target across six analysts is $21.83. The stock is currently trading near its 52-week low, with recent technical signals indicating support at $13.25.
HC Wainwright Maintains $20 Target for Enanta. HC Wainwright reiterated its stance on Enanta Pharmaceuticals, keeping a price target of $20. This view aligns with the broader analyst consensus, where the average target across six analysts is $21.83. The stock is currently trading near its 52-week low, with recent technical signals indicating support at $13.25.